Aug
01
2022
Cyclerion reveals data for schizophrenia therapy
Cyclerion Therapeutics has announced positive top line data from its clinical study of CY6463 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). It concerns individuals …